The Pittsburgh Revolution Fund is targeting a $200m close to support drug research teams that will form spinouts of University of Pittsburgh, according to the Pittsburgh Post-Gazette.
The university’s Drug Discovery Institute will partner the seed-stage fund to develop medicine through quantitative systems pharmacology, which uses interactive computing to predict how drugs affect disease progression.
The fund will focus on breast cancer, neurodegenerative conditions such as Huntington’s disease and Alzheimer’s disease, brain trauma and certain liver diseases.
Targeting research teams working in conjunction with private industry, Bill Newlin, chairman of seed-stage investor Newlin Investment Company, said he expects to give the first grant in early 2018.
